These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34463045)

  • 1. Cases reports: Unintended anti-doping rule violation after dorzolamide use several months prior to a doping control.
    Pokrywka A; Skrzypiec-Spring M; Krzywański J; Rynkowski M; Saugy M; Faiss R
    Drug Test Anal; 2021 Oct; 13(10):1803-1806. PubMed ID: 34463045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of dorzolamide.
    Martens-Lobenhoffer J; Banditt P
    Clin Pharmacokinet; 2002; 41(3):197-205. PubMed ID: 11929320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical drug delivery to the eye: dorzolamide.
    Loftsson T; Jansook P; Stefánsson E
    Acta Ophthalmol; 2012 Nov; 90(7):603-8. PubMed ID: 22269010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide.
    Biollaz J; Munafo A; Buclin T; Gervasoni JP; Magnin JL; Jaquet F; Brunner-Ferber F
    Eur J Clin Pharmacol; 1995; 47(5):455-60. PubMed ID: 7720769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
    Jansook P; Stefánsson E; Thorsteinsdóttir M; Sigurdsson BB; Kristjánsdóttir SS; Bas JF; Sigurdsson HH; Loftsson T
    Eur J Pharm Biopharm; 2010 Oct; 76(2):208-14. PubMed ID: 20637867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pH on the ocular distribution of a topical carbonic anhydrase inhibitor.
    Conroy CW; Maren TH
    Exp Eye Res; 1995 Aug; 61(2):213-22. PubMed ID: 7556485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
    Kadam RS; Jadhav G; Ogidigben M; Kompella UB
    Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
    Hoffmanová I; Sánchez D
    Br J Clin Pharmacol; 2018 Apr; 84(4):796-799. PubMed ID: 29333622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles.
    Park CG; Kim YK; Kim SN; Lee SH; Huh BK; Park MA; Won H; Park KH; Choy YB
    Int J Pharm; 2017 Apr; 522(1-2):66-73. PubMed ID: 28216468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers.
    Gatchev E; Petrov A; Kolev E; Hristova R; Demircheva I; Koytchev R; Richter W; Tegel F; Thyroff-Friesinger U
    Arzneimittelforschung; 2011; 61(5):282-6. PubMed ID: 21755811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor.
    Pfeiffer N
    Surv Ophthalmol; 1997; 42(2):137-51. PubMed ID: 9381367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical carbonic anhydrase inhibitors.
    Talluto DM; Wyse TB; Krupin T
    Curr Opin Ophthalmol; 1997 Apr; 8(2):2-6. PubMed ID: 10168353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats.
    Wong BK; Bruhin PJ; Lin JH
    Pharm Res; 1994 Mar; 11(3):438-41. PubMed ID: 8008713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor.
    Maren TH; Conroy CW; Wynns GC; Levy NS
    J Ocul Pharmacol Ther; 1997 Feb; 13(1):23-30. PubMed ID: 9029437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans.
    Schmitz K; Banditt P; Motschmann M; Meyer FP; Behrens-Baumann W
    Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1621-4. PubMed ID: 10359348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)].
    Lachmann C; Jörg KM; Trinkmann R
    Klin Monbl Augenheilkd; 1998 Dec; 213(6):326-30. PubMed ID: 10048009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Local carbonic anhydrase inhibitor dorzolamide: development and properties].
    Pfeiffer N
    Ophthalmologe; 1996 Feb; 93(1):103-18. PubMed ID: 8867167
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment on traumatic macular hole repair through topical dorzolamide: A case report.
    Panigrahi PK
    Indian J Ophthalmol; 2024 May; 72(5):756-757. PubMed ID: 38648441
    [No Abstract]   [Full Text] [Related]  

  • 20. [Blurred vision after instillation of topical carbonic anhydrase inhibitor].
    Ishibashi T; Mori K
    Nippon Ganka Gakkai Zasshi; 2006 Sep; 110(9):689-92. PubMed ID: 17025224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.